Automated CNN–Based Analysis Versus Manual Analysis for MR Elastography in Nonalcoholic Fatty Liver Disease: Intermethod Agreement and Fibrosis Stage Discriminative Performance

Autor: Guilherme M, Cunha, Timoteo I, Delgado, Michael S, Middleton, Sam, Liew, Walter C, Henderson, Danielle, Batakis, Kang, Wang, Rohit, Loomba, Ryan S, Huss, Robert P, Myers, Claude B, Sirlin, Kathryn J, Fowler, Kyle A, Hasenstab

Publikováno v: American Journal of Roentgenology. 219:224-232

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf23778f93427ee42f8ddc623c1c4db5
https://doi.org/10.2214/ajr.21.27135

Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD

Autor: Ekaterina, Smirnova, Mark D, Muthiah, Nicole, Narayan, Mohamad S, Siddiqui, Puneet, Puri, Velimir A, Luketic, Melissa J, Contos, Michael, Idowu, Jen-Chieh, Chuang, Andrew N, Billin, Ryan S, Huss, Robert P, Myers, Sherry, Boyett, Mulugeta, Seneshaw, Hae-Ki, Min, Faridodin, Mirshahi, Arun J, Sanyal

Publikováno v: Hepatology. 76:1811-1824

Bile acids are hepatic metabolites and have many properties considered to be relevant to the pathophysiology of NAFLD. Circulating levels of the intestinal microbiome-modified bile acid deoxycholate are increased in cirrhosis.To further elucidate the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42e9c204e496a981fe3b9eb32acb3053
https://doi.org/10.1002/hep.32568

Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis

Autor: Eric Lawitz, Manuel Romero-Gómez, Quentin M. Anstee, Stephen A. Harrison, Catherine Jia, Zobair M. Younossi, Chuhan Chung, Zachary Goodman, Robert P. Myers, Ryan S Huss, Michael Trauner, Vincent Wai-Sun Wong, Andrew J. Muir, Takeshi Okanoue, Jaime Bosch, D. Ding, Nezam H. Afdhal, Manal F. Abdelmalek, Ling Han, Arun J. Sanyal

Publikováno v: Sanyal, Arun J; Anstee, Quentin M; Trauner, Michael; Lawitz, Eric J; Abdelmalek, Manal F; Ding, Dora; Han, Ling; Jia, Catherine; Huss, Ryan S; Chung, Chuhan; Wong, Vincent Wai-Sun; Okanoue, Takeshi; Romero-Gomez, Manuel; Muir, Andrew J; Afdhal, Nezam H; Bosch, Jaime; Goodman, Zachary; Harrison, Stephen A; Younossi, Zobair M and Myers, Robert P (2022). Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis. Hepatology, 75(5), pp. 1235-1246. Wiley 10.1002/hep.32204

[Background and Aims] Surrogate endpoints that predict complications are necessary for assessment and approval of NASH therapies. We assessed associations between histologic and noninvasive tests (NITs) of fibrosis with liver‐related complications

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b86f4456e7ab91450afe03ea0eec5b6
https://doi.org/10.1002/hep.32204

Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat

Autor: Eric J, Lawitz, Bal Raj, Bhandari, Peter J, Ruane, Anita, Kohli, Eliza, Harting, Dora, Ding, Jen-Chieh, Chuang, Ryan S, Huss, Chuhan, Chung, Robert P, Myers, Rohit, Loomba

Publikováno v: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol 21, iss 1

Background & aimsPatients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH) are at high risk of morbidity and mortality. We previously found that a combination of the farnesoid X receptor agonist cilofexor (CILO) and the acetyl-CoA ca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::929b2cef2b51a962b092040436babe79
https://escholarship.org/uc/item/1c44j6bg

Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis

Autor: Naim Alkhouri, Anita Kohli, Nadege Gunn, Stephen H. Caldwell, Simone I. Strasser, Robert P. Myers, Mitchell L. Shiffman, Ryan S Huss, Peter Ruane, Zachary Goodman, Kris V. Kowdley, Zobair M. Younossi, Mazen Noureddin, Maria Stepanova, Vincent Wai-Sun Wong, Rohit Loomba, Aasim Sheikh

Publikováno v: Hepatology Communications, Vol 5, Iss 7, Pp 1201-1211 (2021)
Hepatology Communications
Hepatology communications, vol 5, iss 7

Patient‐reported outcomes (PROs) are important endpoints for clinical trials. The impact of investigational drugs on PROs of patients with advanced nonalcoholic steatohepatitis (NASH) was investigated. Patients with NASH with bridging fibrosis or c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc33b91c341cb2f68ed8e0d282539f1d
https://doaj.org/article/10bc3bc5921042808f8b0f85eb39a5a0